Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
Adam K Karlsson,1 Sohag N Saleh2 1Faculty of Medicine, Imperial College London, 2Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK Background and objectives: Rates of malignant melanoma are continuing to increase, and until recently effective treatments were lacking. How...
Main Authors: | Karlsson AK, Saleh SN |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-08-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Subjects: | |
Online Access: | https://www.dovepress.com/checkpoint-inhibitors-for-malignant-melanoma-a-systematic-review-and-m-peer-reviewed-article-CCID |
Similar Items
-
Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
by: Chiao-En Wu, et al.
Published: (2020-06-01) -
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
by: Houssein Safa, et al.
Published: (2019-11-01) -
Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
by: D. D. Sakaeva, et al.
Published: (2020-12-01) -
Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
by: Thilo Gambichler, et al.
Published: (2019-12-01) -
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)